Lilly’s New Anti-Amyloid Play Hinges On Tau Bet

Redesigned Phase III Trial May Confirm Phase II Donanemab Results

 
• By Mandy Jackson
Poker chips on red background
Lilly's bet on donanemab depends on tau levels and tau burden reductions • Source: Shutterstock

More from Clinical Trials

More from R&D